Evidence map›Paper›PMID 39129162›Full record

ArticleCurrent HIV research2024

Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye.

Erkan Yılmaz, Ahmet Furkan Kurt, Mehtap Dogruel, Dilek Yıldız Sevgi, Hayat Kumbasar Karaosmanoglu, Esra Zerdali, Meliha Meric Koc, Bilgul Mete, Fehmi Tabak

Abstract read
PubMed Publisher
In one paragraph

Article in Current HIV research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erkan YılmazTissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey.ORCID 0000-0002-5133-4532
Ahmet Furkan KurtInfectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey.ORCID 0000-0002-7454-7557
Mehtap DogruelTissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey.ORCID 0000-0002-4354-2489
Dilek Yıldız SevgiInfectious Diseases and Clinical Microbiology Department, University of Medical Sciences- Hamidiye Sisli Etfal Research and Training Hospital, Istanbul, Turkey.ORCID 0000-0002-6047-4879
Hayat Kumbasar KaraosmanogluInfectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Bakırkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey.ORCID 0000-0002-7716-3006
Esra ZerdaliInfectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Haseki Research and Training Hospital, Istanbul, Turkey.
Meliha Meric KocInfectious Diseases and Clinical Microbiology Department, Medical School, Bezmialem Vakif University, Istanbul, Turkey.ORCID 0000-0002-0563-6900
Bilgul MeteInfectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey.ORCID 0000-0001-9091-6087
Fehmi TabakInfectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey.ORCID 0000-0001-8632-2825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAbacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye. MATERIAL AND

methodsFive HIV treatment centers in Istanbul included all sequential treatmentnaïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP.

resultsEight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive.

conclusionAlthough previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions. It can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.

Indexed as

DideoxynucleosidesHIV InfectionsHLA-B AntigensAbacavirAdultAllelesAnti-HIV AgentsCyclopropanesDideoxyadenosineDrug HypersensitivityFemaleGene FrequencyGenotypeHumansMaleMiddle AgedAbacavirAnti-HIV AgentsCyclopropanesDideoxyadenosineDideoxynucleosidesHLA-B*57:01 antigenHLA-B57 antigenHLA-B AntigensAbacavirallele carriersantiretroviral therapyHIV-AIDSHLA-B*57:01HSR.

Identifiers

PMID39129162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.